Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
Robichaux, Jacqulyne P JP; Elamin, Yasir Y YY; Vijayan, R S K RSK; Nilsson, Monique B MB; Hu, Lemei L; He, Junqin J; Zhang, Fahao F; Pisegna, Marlese M; Poteete, Alissa A; Sun, Huiying H; Li, Shuai S; Chen, Ting T; Han, Han H; Negrao, Marcelo Vailati MV; Ahnert, Jordi Rodon JR; Diao, Lixia L; Wang, Jing J; Le, Xiuning X; Meric-Bernstam, Funda F; Routbort, Mark M; Roeck, Brent B; Yang, Zane Z; Raymond, Victoria M VM; Lanman, Richard B RB; Frampton, Garrett M GM; Miller, Vincent A VA; Schrock, Alexa B AB; Albacker, Lee A LA; Wong, Kwok-Kin KK; Cross, Jason B JB; Heymach, John V JV